Company Filing History:
Years Active: 2021-2024
Title: Innovations in T Cell Modification by Jonathan Silk
Introduction
Jonathan Silk is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the modification of T cells for therapeutic purposes. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
One of Jonathan Silk's latest patents focuses on T cell modification and its applications. This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, while constitutively expressing an antigen receptor that binds to a tumor antigen. The modified T cells may include a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule and a second nucleotide sequence encoding the antigen receptor. An inducible promoter is operably linked to the first nucleotide sequence, while a constitutive promoter is linked to the second nucleotide sequence. This patent also provides nucleic acid constructs and vectors, as well as T cells that incorporate such constructs and vectors, along with therapeutic methods and uses thereof.
Career Highlights
Jonathan Silk is currently associated with Adaptimmune Limited, a company that specializes in developing T cell therapies for cancer. His work at Adaptimmune has been instrumental in advancing the understanding and application of modified T cells in clinical settings.
Collaborations
Some of Jonathan's notable coworkers include Garth Hamilton and Claire Gueguen. Their collaborative efforts contribute to the innovative research and development at Adaptimmune Limited.
Conclusion
Jonathan Silk's contributions to T cell modification represent a significant advancement in cancer therapy. His innovative patents and work at Adaptimmune Limited are crucial in the ongoing fight against cancer.